UPAR targeted radionuclide therapy with 177Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer

Molecular Pharmaceutics

Volumn 11, Issue 8, 2014, Pages 2796-2806

  Persson, Morten ^a,b,c,d   Juhl, Karina ^b,c   Rasmussen, Palle ^e   Brandt Larsen, Malene ^b   Madsen, Jacob ^b   Ploug, Michael ^a,d   Kjaer, Andreas ^a,b,c  

^a Danish Chinese Center for Proteases and Cancer   (China)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d FINSEN LABORATORY   (Denmark)

^e TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

cancer; CD87; metastases; positron emission tomography; prostate cancer; radiation therapy; radionuclide therapy; theranostics; urokinse type plasminogen activator receptor

Indexed keywords

LIGAND; RADIOPHARMACEUTICAL AGENT; TETRAXETAN AE105 LUTETIUM 177; TETRAXETAN AE105MUT LUTETIUM 177; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; 177LU-DOTA-AE105; COORDINATION COMPOUND; LUTETIUM; OLIGOPEPTIDE; PROTEIN BINDING; RADIOISOTOPE; RECOMBINANT PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BIOLUMINESCENCE; CANCER RADIOTHERAPY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISSEMINATED CANCER; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY PARENCHYMA; METASTASIS FREE SURVIVAL; METASTATIC PROSTATE CANCER; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN INTERACTION; RADIOISOTOPE THERAPY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; CHEMISTRY; DISEASE FREE SURVIVAL; IC50; MALE; METASTASIS; MICRO-COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; SCINTISCANNING; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; CELL LINE, TUMOR; COORDINATION COMPLEXES; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; LUTETIUM; MALE; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; PROTEIN BINDING; RADIOISOTOPES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEINS; TREATMENT OUTCOME; X-RAY MICROTOMOGRAPHY;

EID: 84905454377     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500177c     Document Type: Article

References (48)

1. Walczak, J. R.; Carducci, M. A. Prostate cancer: a practical approach to current management of recurrent disease Mayo Clin. Proc. 2007, 82 (2) 243-249
2. Chi, K. N.; Bjartell, A.; Dearnaley, D.; Saad, F.; Schroder, F. H.; Sternberg, C.; Tombal, B.; Visakorpi, T. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets Eur. Urol 2009, 56 (4) 594-605
3. Duffy, M. J. The urokinase plasminogen activator system: role in malignancy Curr. Pharm. Des. 2004, 10 (1) 39-49
4. Dano, K.; Behrendt, N.; Hoyer-Hansen, G.; Johnsen, M.; Lund, L. R.; Ploug, M.; Romer, J. Plasminogen activation and cancer Thromb. Haemostasis 2005, 93 (4) 676-681
5. Blasi, F.; Sidenius, N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling FEBS Lett. 2010, 584 (9) 1923-1930
6. Noh, H.; Hong, S.; Huang, S. Role of urokinase receptor in tumor progression and development Theranostics 2013, 3 (7) 487-495
7. Rabbani, S. A.; Xing, R. H. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies Int. J. Oncol. 1998, 12 (4) 911-920
8. Miyake, H.; Hara, I.; Yamanaka, K.; Arakawa, S.; Kamidono, S. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer Int. J. Oncol. 1999, 14 (3) 535-541
9. Miyake, H.; Hara, I.; Yamanaka, K.; Gohji, K.; Arakawa, S.; Kamidono, S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer Prostate 1999, 39 (2) 123-129
10. Piironen, T.; Haese, A.; Huland, H.; Steuber, T.; Christensen, I. J.; Brunner, N.; Dano, K.; Hoyer-Hansen, G.; Lilja, H. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum Clin. Chem. 2006, 52 (5) 838-844
11. Shariat, S. F.; Roehrborn, C. G.; McConnell, J. D.; Park, S.; Alam, N.; Wheeler, T. M.; Slawin, K. M. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis J. Clin. Oncol. 2007, 25 (4) 349-355
12. Gupta, A.; Lotan, Y.; Ashfaq, R.; Roehrborn, C. G.; Raj, G. V.; Aragaki, C. C.; Montorsi, F.; Shariat, S. F. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients Eur. Urol. 2009, 55 (5) 1124-1133
13. Milanese, G.; Dellabella, M.; Fazioli, F.; Pierpaoli, E.; Polito, M.; Siednius, N.; Montironi, R.; Blasi, F.; Muzzonigro, G. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer J. Urol. 2009, 181 (3) 1393-1400
14. Almasi, C. E.; Brasso, K.; Iversen, P.; Pappot, H.; Hoyer-Hansen, G.; Dano, K.; Christensen, I. J. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer Prostate 2011, 71 (8) 899-907
15. Kjellman, A.; Akre, O.; Gustafsson, O.; Hoyer-Hansen, G.; Lilja, H.; Norming, U.; Piironen, T.; Tornblom, M. Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening J. Intern. Med. 2011, 269 (3) 299-305
16. Persson M, K. A. Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications Clin. Physiol. Funct. Imaging 2013, 33, 329-337
17. Li, D.; Liu, S.; Shan, H.; Conti, P.; Li, Z. Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy Theranostics 2013, 3 (7) 507-515
18. Ploug, M.; Ostergaard, S.; Gardsvoll, H.; Kovalski, K.; Holst-Hansen, C.; Holm, A.; Ossowski, L.; Dano, K. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation Biochemistry 2001, 40 (40) 12157-12168
19. Kriegbaum, M. C.; Persson, M.; Haldager, L.; Alpizar-Alpizar, W.; Jacobsen, B.; Gardsvoll, H.; Kjaer, A.; Ploug, M. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes Curr. Drug Targets 2011, 12 (12) 1711-1728
20. Persson, M.; Madsen, J.; Ostergaard, S.; Jensen, M. M.; Jorgensen, J. T.; Juhl, K.; Lehmann, C.; Ploug, M.; Kjaer, A. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion J. Nucl. Med. 2012, 53 (1) 138-145
21. Persson, M.; Madsen, J.; Ostergaard, S.; Ploug, M.; Kjaer, A. (68)Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers Nucl. Med. Biol. 2012, 39 (4) 560-569
22. Persson M, H. M.; Madsen, J.; Jørgensen, T. J. D.; Jensen, K. J.; Kjaer, A.; Ploug, M. Improved PET Imaging of uPAR Expression Using new 64Cu-labeled Cross-Bridged Peptide Ligands: Comparative in vitro and in vivo Studies Theranostics 2013, 3 (9) 618-632
23. Ploug, M. Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist Theranostics 2013, 3 (7) 467-476
24. Li, Z. B.; Niu, G.; Wang, H.; He, L.; Yang, L.; Ploug, M.; Chen, X. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET Clin. Cancer Res. 2008, 14 (15) 4758-4766
25. Persson, M.; Liu, H.; Madsen, J.; Cheng, Z.; Kjaer, A. First F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts Nucl. Med. Biol. 2013, 40, 618-624
26. Persson, M.; Rasmussen, P.; Madsen, J.; Ploug, M.; Kjaer, A. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using (177)Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts Nucl. Med. Biol. 2012, 39, 962-969
27. Bergsma, H.; van Vliet, E. I.; Teunissen, J. J.; Kam, B. L.; de Herder, W. W.; Peeters, R. P.; Krenning, E. P.; Kwekkeboom, D. J. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs Best Pract. Res., Clin. Gastroenterol. 2012, 26 (6) 867-881
28. Tomblyn, M. Radioimmunotherapy for B-cell non-hodgkin lymphomas Cancer Control: Journal of the Moffitt Cancer Center 2012, 19 (3) 196-203
29. Jacobsen, B.; Gardsvoll, H.; Juhl Funch, G.; Ostergaard, S.; Barkholt, V.; Ploug, M. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry Protein Expr. Purif. 2007, 52 (2) 286-296
30. Lin, L.; Gardsvoll, H.; Huai, Q.; Huang, M.; Ploug, M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy J. Biol. Chem. 2010, 285 (14) 10982-10992
31. Ronne, E.; Hoyer-Hansen, G.; Brunner, N.; Pedersen, H.; Rank, F.; Osborne, C. K.; Clark, G. M.; Dano, K.; Grondahl-Hansen, J. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies Breast Cancer Res. Treat. 1995, 33 (3) 199-207
32. Kozlowski, J. M.; Fidler, I. J.; Campbell, D.; Xu, Z. L.; Kaighn, M. E.; Hart, I. R. Metastatic behavior of human tumor cell lines grown in the nude mouse Cancer Res. 1984, 44 (8) 3522-3529
33. Forbes, K.; Gillette, K.; Kelley, L. A.; Sehgal, I. Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis World J. Urol. 2004, 22 (1) 67-71
34. Li, Y.; Cozzi, P. J. Targeting uPA/uPAR in prostate cancer Cancer Treat. Rev. 2007, 33 (6) 521-527
35. Nogueira, L.; Corradi, R.; Eastham, J. A. Other biomarkers for detecting prostate cancer BJU Int. 2010, 105 (2) 166-169
36. Rabbani, S. A.; Ateeq, B.; Arakelian, A.; Valentino, M. L.; Shaw, D. E.; Dauffenbach, L. M.; Kerfoot, C. A.; Mazar, A. P. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo Neoplasia 2010, 12 (10) 778-788
37. Abdalla, M. O.; Karna, P.; Sajja, H. K.; Mao, H.; Yates, C.; Turner, T.; Aneja, R. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy J. Controlled Release 2011, 149 (3) 314-322
38. Reber, J.; Haller, S.; Leamon, C. P.; Muller, C. 177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy Mol. Cancer Ther. 2013, 12 (11) 2436-45
39. Wild, D.; Frischknecht, M.; Zhang, H.; Morgenstern, A.; Bruchertseifer, F.; Boisclair, J.; Provencher-Bolliger, A.; Reubi, J. C.; Maecke, H. R. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213 Bi-DOTA-PESIN and 213 Bi-AMBA versus 177Lu-DOTA-PESIN) Cancer Res. 2011, 71 (3) 1009-1018
40. LeBeau, A. M.; Duriseti, S.; Murphy, S. T.; Pepin, F.; Hann, B.; Gray, J. W.; VanBrocklin, H. F.; Craik, C. S. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer Cancer Res. 2013, 73 (7) 2070-2081
41. Sabet, A.; Ezziddin, K.; Pape, U. F.; Reichman, K.; Haslerud, T.; Ahmadzadehfar, H.; Biersack, H. J.; Nagarajah, J.; Ezziddin, S. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with Lu-octreotate Eur. J. Nucl. Med. Mol. Imaging 2013, 41, 505-510
42. Kunikowska, J.; Krolicki, L.; Sowa-Staszczak, A.; Pawlak, D.; Hubalewska-Dydejczyk, A.; Mikolajczak, R. Nephrotoxicity after PRRT-still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE Endokrynologia Polska 2013, 64 (1) 13-20
43. Pyke, C.; Graem, N.; Ralfkiaer, E.; Ronne, E.; Hoyer-Hansen, G.; Brunner, N.; Dano, K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma Cancer Res. 1993, 53 (8) 1911-1915
44. Plesner, T.; Ploug, M.; Ellis, V.; Ronne, E.; Hoyer-Hansen, G.; Wittrup, M.; Pedersen, T. L.; Tscherning, T.; Dano, K.; Hansen, N. E. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils Blood 1994, 83 (3) 808-815
45. Fang, H.; Declerck, Y. A. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials Cancer Res. 2013, 73 (16) 4965-4977
46. Sleeman, J. P. The metastatic niche and stromal progression Cancer Metastasis Rev. 2012, 31 (3-4) 429-440
47. Kam, B. L.; Teunissen, J. J.; Krenning, E. P.; de Herder, W. W.; Khan, S.; van Vliet, E. I.; Kwekkeboom, D. J. Lutetium-labelled peptides for therapy of neuroendocrine tumours Eur. J. Nucl. Med. Mol. Imaging 2012, 39 (Suppl 1) S103-S112
48. Parker, C.; Nilsson, S.; Heinrich, D.; Helle, S. I.; OSullivan, J. M.; Fossa, S. D.; Chodacki, A.; Wiechno, P.; Logue, J.; Seke, M.; Widmark, A.; Johannessen, D. C.; Hoskin, P.; Bottomley, D.; James, N. D.; Solberg, A.; Syndikus, I.; Kliment, J.; Wedel, S.; Boehmer, S.; DallOglio, M.; Franzen, L.; Coleman, R.; Vogelzang, N. J.; OBryan-Tear, C. G.; Staudacher, K.; Garcia-Vargas, J.; Shan, M.; Bruland, O. S.; Sartor, O.; ALSYMPCA Investigators Alpha emitter radium-223 and survival in metastatic prostate cancer N. Engl. J. Med. 2013, 369 (3) 213-223